[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"takotsubo-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:takotsubo-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,69,94,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100390290","the-german-italian-spanish-takotsubo-geist-registry-100390290",false,"NCT04361994","The GErman Italian Spanish Takotsubo (GEIST) Registry","GEIST","Inclusion Criteria:\n\n* Patients with Takotsubo syndrome\n\nExclusion Criteria:\n\n* Non","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","6 Months","OBSERVATIONAL","GEIST is a multicenter, international observational registry of patients with Takotsubo syndrome. Data regarding the clinical profile (demographic characteristics, clinical presentation, laboratory measures, electrocardiography \u002Fechocardiography \u002F coronary angiography parameters, treatment and medication), in-hospital course and complications and short-\u002Flong-term outcome are collected prospectively and retrospectively to increase the understanding of the disease.",[25],"Takotsubo Syndrome","RECRUITING","2025-12-18",{"date":29,"type":30},"2025-12-26","ACTUAL",{"date":32,"type":30},"2015-04",{"date":34,"type":20},"2035-12",{"name":36,"class":37},"Prof. Dr. med. Ingo Eitel","OTHER",2,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":57,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100589414","mechanisms-and-prognosis-of-stroke-heart-syndrome-100589414","NCT06954103","Mechanisms And Prognosis of Stroke-Heart Syndrome","MAP-SHS","Inclusion Criteria:\n\n1. Patients admitted within 48 hours of onset, confirmed by CT\u002FMRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).\n2. Moderate-to-severe stroke with NIHSS ≥ 5.\n\nExclusion Criteria:\n\n1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).\n2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).\n3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).\n4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).\n5. Concomitant systemic diseases such as renal failure (eGFR \\\u003C 30), autoimmune disorders, severe infections, etc.\n6. History of dementia, depression, or other psychiatric disorders.\n7. Poor compliance and inability to cooperate with follow-up.",{"count":47,"type":20},658,"The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.",[50,51,52,53,54,55,25,56],"Stroke","Myocardial Injury","Heart Failure","Acute Coronary Syndromes","Arrhythmia","Sudden Cardiac Death","Heart Rate Variability",[58],"Stroke-heart syndrome","2025-04-23",{"date":61,"type":30},"2025-05-01",{"date":63,"type":30},"2025-03-01",{"date":65,"type":20},"2028-04-01",{"name":67,"class":37},"Chensheng Pan",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100413658","phase-4-broken-swedeheart--optimized-pharmacological-treatment-for-broken-heart-takotsubo-syndrome-100413658","NCT04666454","BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.","BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome. A Multinational, Multicentre, Registry-based, Open-label, Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. A clinical diagnosis of TS (see definition 2.1), including an ejection fraction (EF) ˂ 50 % at baseline\n3. Written informed consent obtained\n\nExclusion Criteria:\n\n1. Previous randomization in the trial\n2. Any concomitant condition resulting in a life expectancy of less than one month\n3. Previously diagnosed left ventricular ejection fraction \\\u003C50%\n4. Known cardiomyopathy (except previous Takotsubo syndrome)\n5. Known hemodynamically significant valve disease (moderate or severe aortic\u002Fmitral regurgitation) or stenosis\n6. Heart transplant or left ventricular assist device recipient\n7. Most recent (within the most recent 3 months) haemoglobin ˂10 g\u002FdL\n8. Systolic blood pressure \\\u003C80 mm Hg at screening\n9. Estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2\n10. Current dialysis\n11. Pregnancy or of childbearing potential who is not sterilized or is not using a medically accepted form of contraception\n12. Not suitable in the opinion of the investigator due to severe or terminal comorbidity with poor prognosis, or characteristics that may interfere with adherence to the trial protocol\n\n    Specific exclusion criteria for Randomization 1\n13. Any contra-indication for treatment with adenosine or dipyridamole (including AV-block II and III, sick-sinus syndrome in subjects who don´t have a functioning pacemaker, unstable angina, ongoing treatment with dipyridamole)\n14. Severe asthma (defined as asthma requiring medium or high-dose inhaled corticosteroids combined with other long-acting medications) and severe Chronic Obstructive Pulmonary Disease (COPD), (defined as FEV-1 ˂ 50 %)\n15. Ongoing treatment with dipyridamole\n16. Declined participation in study 1\n\nSpecific exclusion criteria for Randomization 2\n\n1. Any contra-indication for anticoagulant treatment.\n2. Current indication for treatment with, anticoagulant or dual antiplatelet therapy\n3. Declined participation in study 2",{"count":77,"type":20},1000,"INTERVENTIONAL",[80],"PHASE4","The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.",[25],"2024-11-26",{"date":85,"type":30},"2024-12-02",{"date":87,"type":30},"2020-12-14",{"date":89,"type":20},"2028-12",{"name":91,"class":92},"Vastra Gotaland Region","OTHER_GOV",16,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":68},"100495487","takotsubo-syndrome-and-air-pollution-100495487","NCT05731830","Takotsubo Syndrome and Air Pollution","Takotsubo Syndrome and Air Pollution: the \"Tako-Air\" Study","Tako-Air","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of TTS.\n* Available data for short-term and\u002For long-term exposure to air pollutants (see below).\n* Written informed consent to participate.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Not available data for short-term and\u002For long-term exposure to air pollutants.",{"count":103,"type":20},250,"Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury characterized by typical regional wall motion abnormalities in the absence of culprit epicardial coronary artery disease frequently precipitated by significant emotional stress or serious physical illness. The clinical presentation is usually similar to acute myocardial infarction (MI), with chest pain and\u002For dyspnea, ST-segment elevation or depression and\u002For T-wave inversion on the resting electrocardiogram (ECG) and elevation of serum cardiac troponin. Although previously considered a benign disease, it is now clear that TTS is associated with severe acute complications during the acute phase including hemodynamic and electrical instability and up to 5% of in-hospital mortality.\n\nThe pathogenetic mechanisms of air pollution are likely to predispose to the occurrence as well as to mediate a worse clinical presentation and outcome of TTS, proving air pollution as a TTS risk factor.",[25],[107,25,108],"Air Pollution","Stress cardiomyopathy","2024-02-23",{"date":111,"type":30},"2024-02-26",{"date":113,"type":30},"2022-11-15",{"date":115,"type":20},"2026-11",{"name":117,"class":37},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":126,"studyType":22,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":68},"100411205","polish-registry-of-takotsubo-syndrome-100411205","NCT04634487","Polish Registry of Takotsubo Syndrome","Pol-Tako","Inclusion Criteria:\n\nall patients with takotsubo syndrome\n\nExclusion Criteria:\n\n\\-",{"count":77,"type":20},"10 Years","Polish registry of takotsubo syndrome",[25],"2020-11-12",{"date":131,"type":30},"2020-11-18",{"date":133,"type":30},"2020-10-01",{"date":135,"type":20},"2030-01",{"name":137,"class":37},"Medical University of Warsaw"]